medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2005, Número 2

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2005; 3 (2)


Anticuerpos para las enfermedades sistémicas autoinmunes. Usos en dermatología. I parte

Miniño M

Idioma: Español
Referencias bibliográficas: 65
Paginas: 96-104
Archivo PDF: 350.40 Kb.


RESUMEN

Se realiza una revisión de los principales anticuerpos presentes en las enfermedades sistémicas autoinmunes y sus asociaciones, en entidades tales como lupus eritematoso, esclerodermia sistémica, poli-dermatomiositis, vasculitis y enfermedad mixta del tejido conectivo. Se comentan los anticuerpos antinucleares, anti-ADN, complementos, anti-Ro(ss-A), anti-La(ss-B), anti-Sm, histonas, anti-RNP, ANCA y P-ANCA, cardiolipinas, anticoagulante lúpico, fosfatidilserina y anticuerpos para dermatomiositis, entre otros.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Sontheimer R., Provost T. Cutaneous manifestation of Rheumatic Diseases. Williams & Wilkins, Baltimore, 1996: 7-8

  2. Suárez-Almanzor ME, González-López L, Gámez-Nava JI, Belseck E, Kendall CJ, Davis P. Utilization and predictive value of laboratory tests in patients referred to rheumatologists by primary care physicians. J Rheumatol 1998; 25: 1980-1985

  3. Mutasin D, Adams B. Practical guidelines for serologic evaluation of immune connective diseases. J Am Acad Dermatol 2000; 42: 159-174

  4. Lane S, Gravel J. Clinical Utility of Common Serum Rheumatologic Tests. Am Fam Physician 2002; 65:1073-1080

  5. Ward MM. Laboratory testing for systemic rheumatic diseases. Postgrad Med 1998; 103: 93-100

  6. Cabral AR, Alarcón-Segovia D. Autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 1998; 10: 409-416

  7. Clinical Diagnosis and Management by Laboratory Methods, 19th ed., John B. Henry (ed.). Philadelphia; WB Saunders Company, 1996: 1014, 1040

  8. Fishbach, FA. Manual of Laboratory and Diagnostic Tests. 5th ed. Philadelphia: Lippincott 1996: 575, 579-580

  9. Lehman, CA. Saunders Manual of Clinical Laboratory Science. Philadelphia: WB Saunders Company 1998: 296-299

  10. Mayo Medical Laboratories. Interpretative Handbook. Rochester, Minnesota; 1999: 59

  11. Pagana KD, Pagana TJ. Manual of Diagnostic and Laboratory Tests. St. Louis, Mosby, 1998: 76-79

  12. Pahor A, Kranj I, Gorenjak M, Holc I. The clinical significance of antinuclear antibodies in connective tissue disease. Wien Klin Wochenschr 1998; 110: 338

  13. Thomas FC, Robinson JA. The antinuclear antibody test. When is a positive result clinically relevant? Postgrad Med 1993; 94 (2): 55-58, 63, 66

  14. Evans J. Antinuclear antibody testing in systemic autoimmune disease. Clin Chest Med 1998; 19: 613-625

  15. Osterland CK. Laboratory diagnosis and monitoring in chronic systemic autoimmune diseases. Clin Chem 1994; 40: 2146-2153

  16. Slater CS, Davis R, Shmerling R. Antinuclear Antibody Testing. A Study of Clinical Utility. Arch Int Med 1996: 1421-1425

  17. Malleson PN, Sailer M, Mckinnon MJ. Usefulness of antinuclear testing to screen rheumatic diseases. Arch Dis Child 1997; 77; 299-304

  18. Peng SL, Hardin JA, Craft J. “Antinuclear antibodies”. In: Kelley WN et al (eds). Textbook of rheumatology. 5th ed. Philadelphia: Saunders, 1997: 250-266

  19. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989; 44: 93-151

  20. Tan EM. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 1982; 33: 167-239

  21. Myckatyn S, Russell A. Outcome of Positive Antinuclear Antibodies in individuals without Connective Tissue Disease. J Rheumatol 2003; 30: 736-739

  22. Arbuckel MR, McClain MT, Rubertone MV, Scofield H, Dennis GJ, Jame JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349 (16): 1526-1533

  23. Jaskowski TD. Screening for antinuclear antibodies by enzyme inmunoassay. Am J Clin Pathol 1996; 105 (4): 468-473

  24. Gill J, Quisel A, Rocca P, Walters D. Diagnosis of Systemic Lupus Erythematosus. Am Fam Physician 2003; 68: 2179-2186

  25. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 2000; 124: 71-81

  26. Diamond B, Katz JB, Paul E, Aranow C, Lutsgarten D, Scharff MD. The role of somatic mutation in the pathogenic anti-ADN response. Ann Rev Inmunol 1992; 10: 731-757

  27. Limpanasithikul W, Ray S, Diamond B. Cross-reactive antibodies that have both protective and pathogenic potential. J Inmunol 1995: 155: 967-973

  28. Schwartz RS, Stollar BD. Origins to anti-DNA antibodies (Review). J Clin Invest 1985; 75: 321-327

  29. Shimerling RH. Rheumatic disease: choosing the most useful diagnostic tests. Geriatrics 1996; 51: 22-26, 29-30, 32

  30. Somerfield SD et al. Double-stranded DNA antibodies: comparison of four methods of detection. J Clin Pathol 1981; 34:1032-1035

  31. Reeves WH, Satoh M, Wang J, Chou CH, Ajmani AK. Systemic lupus erythematosus. Antibodies to DNA, DNA-binding proteins, and histones. Rheum Dis Clin North Am 1994; 20: 1-28

  32. Ruddy S. “Complement”. In: NR Rose, eds. Manual of clinical laboratory immunology. 4th ed., Washington, Am Soc Microbiol, 1992: 114-123

  33. Frank M. Detection of complement in relation to disease. J Allergy Clin Imm 1992; 89: 641-648

  34. Herbert LA et al. Diagnostic significance of hypocomplementemia. Kidney Int 1991; 39: 811-821

  35. Schur PH. Complement studies of sera and other biologic fluids. Hum Pathol 1988; 14: 338-342

  36. Shibata S, Sasak T, Hirayashi Y, Seino J, Okamura K et al. Risk factors in the pregnancy for patient with systemic lupus erythematosus: Association with hypocomplementemia with poor prognosis. Ann Rehum Dis 1992; 51: 619-623

  37. Helm KF, Pelers MS. Deposition of membrane attack inmune complex in cutaneous lesions of systemic lupus erythematosus. J Am Acad Dermatol 1993; 28: 687-691

  38. Marcus-Bagley D, Alper CA. “Methods for allotyping complement proteins”. In: Manual of clinical laboratory immunology. 4th ed. NR Rose et al (eds). 1992; Washington: Am Soc Microbiol, 124-125

  39. Shur SD, Hill HR. Immunodeficiency in the 1990s. Pediatr Infect Dis J 1991; 10: 595-611

  40. Habest WJ, Hoet MH, van Venrooij WJ. Epitope patterns of ant-RNP antibodies in rheumatic diseases. Arthritis Rheum 1990; 33: 834-841

  41. Craft J. Antibodies to snRNPs in systemic lupus erythematosus. Rheum Fis Clin North Am 1992; 18: 311-335

  42. Snowden N, Hay E, Holt PJ, Bernstein R. Clinical course of patients with anti-RNP antibodies [Letter]. J Rheumatol 1993; 20: 1256-1258

  43. Schett G, Rubin RL, Steiner G, Hiesberger H, Muller S, Smolen J. The lupus erythematosus cell phenomenon. Comparative analysis of anti-chromatin antibody specificity in lupus erythematosus cell-positive and -negative sera. Arthritis Rheum 2000; 43: 420–428

  44. Harley JB, Scofield RH, Reichlin M. Anti-Ro in Sjögren’s syndrome and systemic lupus erythematosus. Rheum Dis Clin North Am 1992;18: 337-358

  45. Alexander EL et al. Ro (SSA) and La (SSB) antibodies in the clinical spectrum of Sjögren’s syndrome. J Rheumatol 1982; 9: 239-246

  46. Provost TT, Watson R, Simmons-O´Brien E. Significance of the anti-Ro (SS-A) antibody in the evaluation of cutaneus manifestations of a connective disease. J Am Acad Dermatol, 1996; 35: 147-169

  47. Cervera R, Viñas O, Ramos-Casals M, Font J, García-Carrasco M, Sisó A, Ramírez F, Machuca Y, Vives J, Ingelmo M, Burlingame RW. Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Rheumatology 2003; 42 (9): 1131

  48. Jaskowski TD et al. Comparison of three commercially available enzyme immunoassays for the screening of autoantibodies to extractable nuclear antigens. J Clin Lab Anal 1994.

  49. Zimmermann , Smolen JS, Graninger W, Petera P, Fabini G, Hassfeld W et al. Fine specificity of Anti-Ro(SS-A) autoantibodies and clinical manifestations of patients with systemic lupus erythematosus. J Rheumatol 1996; 23: 1897-1903

  50. Ben-Chetrit E. Anti-Ro /La antibodies and their clinical associations. Isr J Med Sci 1997; 33: 251-253

  51. St. Clair EW. Anti-La antibodies. Rheum Dis Clin North Am 1992; 18: 359-376

  52. Wasicek CA, Reichlich M. Clinical and serologic differences between systemic lupus erythematosus with antibodies in Ro vs patients to Ro and La. J Clin Invest 1982, 69: 835-843

  53. Jul K, Hurk P, Kaafa R, Heidaka R, Immoren I, Chen K, Wallgren E, Freman C. Isolated congenital heart block long term outcome of mothers and characterization of the immune response to SS-A/Ro and SS-B/La. Arthtritis Rheum 1993; 1588-1598

  54. Askanase AD, Friedman DM, Copel J, Dische MR, Dubin A, Starc TJ et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus 2002; 11: 145

  55. Lee LA, Roberts CM, Frank MB, McCubbin VR, Reichlin M. The antibody response to Ro /La in cutaneus lupus erythematosus. Arch Dermatol 1994; 130: 1262-1268

  56. Sharp GC. Anti-snRNP and anti-Sm antibodies. Arth Rheum 1982; 25: 757-760

  57. Homma M, Mimori T, TakedaY, Akama H, Yoshida T, Ogasawara T et al. Autoantibodies to the Sm antigen: inmunological approach to clinical aspects of systemic lupus erythematosus. J Rheumatol 1987; 13: 188-193

  58. Snowden N, Hay E, Holt PJ, Bernstein R. Clinical course of patients with anti-RNP antibodies [Letter]. J Rheumatol 1993; 20: 1256-1258

  59. Lundberg I, Nyman U, Hedfors E. Clinical manifestations of anti(U1)snRNP antiboidies: a prospective study of 29 anti-RNP positive patients. Br J Rheumatol 1992; 31: 811-817

  60. Reichlich M, van Venrooij WJ. Autoantibodies to the 1RNP particles: relationship to clinical diagnosis and nephritis. Clin Exp & Inmunol 1991: 83: 286-290

  61. Pironcheva G, Russev G. Characterization of the protein moiety of U7 small nuclear ribonucleoprotein particles. Microbiology, 1994; 77: 41-46

  62. Tanimoto K. Mixed Connective Tissue Disease. Nippon Rinsho, 1994; 52: 2120-2122

  63. López-Longo FJ, Monteagudo I, González CM, Moreno AC, Mahou MR, Grau R et al. Anti-BB´-Sm antibodies, anticardiolipin antibodies and thrombosis in systemic lupus erythematosus. J Rheumatol 1998; 25: 1743- 1749

  64. Ikeda , Takasaki Y, Hirokawa K, Takeuchi K, Hashimoto H. Clinical Significance of Antibodies to TS1-RNA in Patients with Mixed Connective Tissue Disease. J Rheumatol 2003; 30: 998-1005

  65. Reuter R, Rothe S, Habets W, van Venrooij W, Lührmann R. Autoantibody production against the U small nuclear ribonucleoprotein particle proteins E, F, and G in patients with connective diseases. Eur J Inmunol 1990; 20: 437-440




2020     |     www.medigraphic.com